Yun-Chao Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yun-Chao Gao has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Hankui Lu
2 shared publicationsH.‐K. Lu
The Immunoassay Laboratory, Department of Nuclear Medicine, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China
1 shared publicationHan-Kui Lu
Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University
1 shared publication- Hankui Lu
Department of Nuclear Medicine, Shanghai Jiaotong University, Affiliated Sixth People's Hospital, Shanghai, China.
1 shared publication Hong Chai
Shanghai Jiao Tong University Affiliated Sixth People’s Hospital
1 shared publicationHu Zhang
Fudan University Pudong Medical Center
1 shared publication
Latest Publications
- 6 June 2017
- Published by Springer Nature in Current Medical Science
- Vol. 37 (3) , 429-432
Optimal threshold of stimulated serum thyroglobulin level for 18F-FDG PET/CT imaging in patients with thyroid cancer
- 6 June 2017
- Published by Springer Nature in Current Medical Science
- Vol. 37 (3) , 429-432
Optimal threshold of stimulated serum thyroglobulin level for 18F-FDG PET/CT imaging in patients with thyroid cancer
- 1 February 2010
- Published by Elsevier in Clinical Biochemistry
- Vol. 43 (3) , 291-295
Predictive value of osteocalcin in bone metastatic differentiated thyroid carcinoma
- 1 February 2010
- Published by Elsevier in Clinical Biochemistry
- Vol. 43 (3) , 291-295
Predictive value of osteocalcin in bone metastatic differentiated thyroid carcinoma
- 1 January 2010
- Vol. 56, 87-93
Bone turnover markers in patients with differentiated thyroid carcinoma after levothyroxine withdrawal.
Patients receiving postoperative radioiodine therapy for advanced differentiated thyroid carcinoma (DTC) are repeatedly in short-term thyroid hormone deficiency, whose bone turnover state is not fully understood. Serum bone turnover markers (BTMs), bone specific alkaline phosphatase (BALP), type 1 procollagen N-terminal propeptide (P1NP), osteocalcin (OC), and the beta-isomerized C-terminal telopeptide of type 1 collagen (beta-CTx) were measured in 50 adult male DTC patients after 4-week suspension of levothyroxine replacement therapy and 40 matched euthyroid controls. Relationships between parameters of thyroid function (free triiodothyronine, FT3; free thyroxine, FT4; thyroid stimulating hormone, TSH) and the BTMs were studied. The patients had significantly decreased OC (-37.6%, P<0.001) and beta-CTx (-35.5%, P<0.001) compared with the controls, showing FT3 as the independent risk factor for OC (R2=0.425, P<0.001) and beta-CTx (R2=0.124, P<0.001). Partial correlation analysis showed that only FT3 was significantly correlated with OC after controlling FT4 and TSH (r=0.362, P=0.001). DTC patients have moderately decreased bone turnover after short-term suspension of thyroxine suppressive therapy, with serum FT3 concentration as the predominant and independent risk factor.
- 1 January 2010
- Vol. 56, 87-93
Bone turnover markers in patients with differentiated thyroid carcinoma after levothyroxine withdrawal.
Patients receiving postoperative radioiodine therapy for advanced differentiated thyroid carcinoma (DTC) are repeatedly in short-term thyroid hormone deficiency, whose bone turnover state is not fully understood. Serum bone turnover markers (BTMs), bone specific alkaline phosphatase (BALP), type 1 procollagen N-terminal propeptide (P1NP), osteocalcin (OC), and the beta-isomerized C-terminal telopeptide of type 1 collagen (beta-CTx) were measured in 50 adult male DTC patients after 4-week suspension of levothyroxine replacement therapy and 40 matched euthyroid controls. Relationships between parameters of thyroid function (free triiodothyronine, FT3; free thyroxine, FT4; thyroid stimulating hormone, TSH) and the BTMs were studied. The patients had significantly decreased OC (-37.6%, P<0.001) and beta-CTx (-35.5%, P<0.001) compared with the controls, showing FT3 as the independent risk factor for OC (R2=0.425, P<0.001) and beta-CTx (R2=0.124, P<0.001). Partial correlation analysis showed that only FT3 was significantly correlated with OC after controlling FT4 and TSH (r=0.362, P=0.001). DTC patients have moderately decreased bone turnover after short-term suspension of thyroxine suppressive therapy, with serum FT3 concentration as the predominant and independent risk factor.
- 1 June 2008
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 8 (2) , 87-91
Comparison of free plasma metanephrines enzyme immunoassay with 131I-MIBG scan in diagnosis of pheochromocytoma
- 1 June 2008
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 8 (2) , 87-91
Comparison of free plasma metanephrines enzyme immunoassay with 131I-MIBG scan in diagnosis of pheochromocytoma
- 1 June 2007
- Published by Elsevier in Clinical Biochemistry
- Vol. 40 (9-10) , 735-738
Mutual interference between serum thyroglobulin and antithyroglobulin antibody in an automated chemiluminescent immunoassay
- 1 June 2007
- Published by Elsevier in Clinical Biochemistry
- Vol. 40 (9-10) , 735-738
Mutual interference between serum thyroglobulin and antithyroglobulin antibody in an automated chemiluminescent immunoassay
- 1 January 2007
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 67 (7) , 741-747
Effect of freeze–thaw cycles on serum measurements of AFP, CEA, CA125 and CA19‐9
AFP, CEA, CA125 and CA19‐9 are commonly used serum tumour markers (TMs) in clinical practice, although their quantification by immunoassay may be influenced by pre‐analytical sample handling. Though the effect of repetitive freeze–thaw cycles is generally recognized, it is not clear in detail. The present study measured (CLIA) these TMs in serum samples freshly separated and after each of five freeze–thaw cycles, in which the samples were frozen at −40°C for 10 months at cycle 4 and 2 h at other cycles. Statistical analysis with the General Linear Model for Repeated Measures revealed significant decreases in the measurements of the four TMs, with the least decrease of 6.8 % for CA125 and the most decrease of 18.2 % for CA19‐9 after the last cycle, and an overwhelming single cycle decrease of mean 7.7 % at cycle 4 for AFP, CEA and CA125, of 7.5 % and 9.3 % at cycles 4 and 5 for CA19‐9. So it seems that measurements of AFP, CEA and CA125 are more readily affected by long‐term frozen storage compared with frequent freezing–thawing, while CA19‐9 is relatively unstable under both conditions.
- 1 January 2007
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 67 (7) , 741-747
Effect of freeze–thaw cycles on serum measurements of AFP, CEA, CA125 and CA19‐9
AFP, CEA, CA125 and CA19‐9 are commonly used serum tumour markers (TMs) in clinical practice, although their quantification by immunoassay may be influenced by pre‐analytical sample handling. Though the effect of repetitive freeze–thaw cycles is generally recognized, it is not clear in detail. The present study measured (CLIA) these TMs in serum samples freshly separated and after each of five freeze–thaw cycles, in which the samples were frozen at −40°C for 10 months at cycle 4 and 2 h at other cycles. Statistical analysis with the General Linear Model for Repeated Measures revealed significant decreases in the measurements of the four TMs, with the least decrease of 6.8 % for CA125 and the most decrease of 18.2 % for CA19‐9 after the last cycle, and an overwhelming single cycle decrease of mean 7.7 % at cycle 4 for AFP, CEA and CA125, of 7.5 % and 9.3 % at cycles 4 and 5 for CA19‐9. So it seems that measurements of AFP, CEA and CA125 are more readily affected by long‐term frozen storage compared with frequent freezing–thawing, while CA19‐9 is relatively unstable under both conditions.